Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Categories
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Emerging Therapies for Lipid Disorders: PCSK9 Inhibitors and Beyond

Medically reviewed by 
 
Emerging Therapies for Lipid Disorders: PCSK9 Inhibitors and Beyond

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, emphasizing the importance of managing risk factors to prevent these life-threatening conditions.  Lipid disorders contribute significantly to the development of atherosclerosis and related cardiovascular events. As our understanding of lipid metabolism evolves, recent advancements in treatment options are paving the way for more targeted and effective interventions.

This article focuses on PCSK9 inhibitors and other emerging therapies, providing an update on cutting-edge treatments for lipid disorders. It aims to empower healthcare practitioners to make informed decisions that optimize patient outcomes in the realm of lipid management.

[signup]

What are Lipid Disorders?

Lipid disorders, also called dyslipidemia or hyperlipidemia, are characterized by abnormal levels of fats in the blood, including cholesterol and triglycerides. This may be influenced by a variety of factors, such as lifestyle, family history, and the presence of other underlying medical conditions like obesity or thyroid issues. When left untreated, serious consequences may result, including heart attack or stroke.

Traditional treatment methods for hyperlipidemia, while often highly effective, have several limitations, especially in certain patient populations.  

Statins are the most commonly prescribed medication for lipid management. These drugs work by reducing the amount of cholesterol made by the liver and enhancing the clearance of cholesterol from the blood. Some individuals face challenges in reaching target cholesterol levels due to resistance to statins, while others, who are intolerant to these medications, may suffer from severe myopathy (muscle pain), which is a prevalent side effect linked to statin use.

Statins should be avoided in pregnant women and breastfeeding mothers, as cholesterol is essential for fetal development. Those with liver disease should also avoid these drugs, as statins can elevate liver enzymes, further worsening the condition.

Additionally, statins can exacerbate blood sugar issues in patients with type 2 diabetes, increasing the risk of disease progression and the need for insulin treatment. Given the widespread prevalence of diabetes, with nearly 40% of diabetics having high cholesterol concurrently, alternative therapies are necessary.

While statins play a critical role in managing cardiovascular risk for many, healthcare practitioners must assess individual patient profiles to identify suitable treatments.

The Role of PCSK9 in Lipid Metabolism

PCSK9 (proprotein convertase subtilisin/kexin type 9) stands as a crucial enzyme in cholesterol metabolism and a groundbreaking target for treating lipid disorders.

PCSK9 regulates the degradation of low-density lipoprotein receptors (LDLRs) found on the surface of cells. LDLRs are responsible for capturing low-density lipoprotein (LDL) particles, commonly known as “bad cholesterol,” from the bloodstream. By breaking down LDLRs, PCSK9 makes it more difficult for the body to remove LDL from the blood, consequently elevating cholesterol levels and increasing the risk of cardiovascular disease. While this enzyme is necessary for regulating LDLRs and maintaining a delicate balance, excessive PCSK9 activity leads to an unfavorable shortage of receptors.

Understanding PCSK9's function has led to the development of innovative therapies for hyperlipidemia and cardiovascular diseases. Strategies targeting PCSK9 have demonstrated promise in reducing LDL levels and preventing cardiovascular events. Beyond its involvement in lipid metabolism, PCSK9 is involved in various other pathologies, including liver diseases, infectious diseases, autoimmune, and neurocognitive disorders, highlighting its multifaceted significance in health and disease.

PCSK9 Inhibitors: Mechanism of Action and Clinical Benefits

PCSK9 inhibitors are cholesterol-lowering drugs that exert their effects through three primary mechanisms:

Inhibiting Binding: Monoclonal antibodies, a type of protein engineered in a laboratory, are designed to bind to certain targets in the body. Specialized drugs exist to bind PCSK9 in the bloodstream, helping to decrease levels. This prevents the breakdown of LDLRs on cell surfaces, promoting the removal of LDL from the blood. Alirocumab and evolocumab are examples of drugs in this category.

Inhibiting Synthesis: Other PCSK9-inhibiting drugs, such as inclisiran, intervene at the genetic level. By silencing messenger RNA (mRNA), a molecule responsible for PCSK9 production, these drugs inhibit the synthesis of PCSK9.

Inhibiting Maturation: Another approach disrupts PCSK9’s natural maturation process, hindering its release from cells. This is a second mechanism by which inclisiran manages cholesterol.

These novel medications may be used either independently or in conjunction with statins or other lipid-lowering drugs to enhance cholesterol management. Statin drugs, known for reducing cholesterol production in the body, have been shown to increase PCSK9 levels in the blood. Consequently, there is speculation that inhibiting PCSK9 may complement the LDL-lowering effects of statins.  

It is important to differentiate that while statins primarily reduce the amount of cholesterol made in the body, PCSK9 inhibitors influence how cholesterol is cleared from the bloodstream. Statins are taken orally daily, whereas PCSK9 inhibitors are injectable drugs administered every 2-4 weeks.

Additionally, PCSK9 inhibitors exhibit several effects beyond LDL reduction that further differentiate them from statins. Notably, they may reduce lipoprotein(a) (Lp(a)), a form of LDL that has been linked to serious cardiovascular issues. Contrary to statins, PCSK9 inhibitors have not been associated with increased diabetes risk.

In a clinical trial involving over 27,000 patients on statin therapy, those receiving evolocumab injections experienced a remarkable 59% reduction in LDL levels compared to the placebo group. This translated to a 15% decrease in the risk of cardiovascular events, with no significant difference in adverse events between groups.

Another clinical trial compared the efficacy and safety of biweekly and monthly doses of evolocumab with placebo and oral ezetimibe (another type of cholesterol-lowering drug) in hyperlipidemic patients. Evolocumab demonstrated a significant reduction in LDL levels compared to both placebo and ezetimibe, with positive impacts on other lipid levels. The treatment was well-tolerated, marking a significant advancement in stand-alone therapy with PCSK9 inhibitors.

PCSK9 inhibitors emerge as a promising option in cholesterol management, offering diverse mechanisms of action and demonstrating notable efficacy in clinical trials. These findings underscore their potential to transform cardiovascular care.

Emerging PCSK9 Inhibitors on the Market

Several PCSK9 inhibitors are currently approved for use:

Alirocumab:

  • Indications: Adults with hyperlipidemia, homozygous familial hypercholesterolemia (a genetic condition that causes high cholesterol), and prevention of cardiovascular events in those with established cardiovascular disease.
  • Dosing: 75 mg subcutaneous injection every 2 weeks, or 300 mg every 4 weeks. May be increased to a maximum of 150 mg every 2 weeks as needed.

Evolocumab:

  • Indications: Similar to alirocumab, with additional approval for children (at least 10 years old) with genetic hyperlipidemia.
  • Dosing: 140 mg every 2 weeks or 420 mg every 4 weeks (subcutaneous injection). For children with heterozygous familial hypercholesterolemia (a genetic condition where 1 of the 2 genes is affected), dosing is the same as for adults. For adults and children with homozygous familial hypercholesterolemia (both genes are affected, causing more severe symptoms), the dosing is 420 mg every 4 weeks but may be increased to every 2 weeks as needed.

Inclisiran:

  • Indications: Heterozygous familial hypercholesterolemia.
  • Dosing: 284 mg subcutaneous injection initially, then at 3 months, and subsequently every 6 months.

It’s important to note that these are general guidelines, and individual doses may vary based on health history.

Clinical trial data consistently support the efficacy and safety of alirocumab and evolocumab in reducing LDL and preventing cardiovascular events. Inclisiran, a newer drug, also exhibits effective, safe, and well-tolerated LDL cholesterol reduction in high-risk patients in long-term trials.

Beyond PCSK9 Inhibitors: Novel Approaches in Development

Other innovative therapies and approaches are currently in development for managing lipid disorders.

Gene editing is a promising technology with the potential to revolutionize dyslipidemia treatment. It involves making alterations to the DNA (genetic material) in a living organism to modify how the genes are expressed, or how they function. However, because it involves altering an organism's genetic code, it raises ethical and safety considerations that need careful attention.

RNA interference (RNAi) therapies are another promising approach. RNAi is a process where specific types of RNA molecules can turn off or decrease the activity of certain genes in the body, helping to regulate how these genes function. Scientists are exploring ways to apply these treatments to lipid disorders.

Beyond PCSK9, other novel targets for lipid management include:

  • Adenosine triphosphate–citrate lyase (ACLY): Bempedoic acid, an FDA-approved daily medication, reduces LDL by inhibiting ACLY, an enzyme promoting lipid production.
  • Angiopoietin-like protein 3 (ANGPTL3): Evinacumab, a monoclonal antibody, lowers LDL independently of LDL receptors (LDLRs) by inhibiting ANGPTL3, a protein involved in lipid metabolism.
  • Cholesteryl ester transfer protein (CETP): Obicetrapid is currently in clinical trials for its capacity to inhibit CETP, a protein that facilitates the transfer of fats between different lipoproteins in the bloodstream. This drug shows potential in reducing LDL and decreasing the risk of cardiovascular events.

Challenges and Considerations in Implementing New Therapies

Incorporating these novel treatments for lipid disorders into clinical practice presents several challenges for healthcare practitioners.

First, the high cost of innovative therapies can be a significant barrier, limiting accessibility for both providers and patients. Navigating insurance coverage and reimbursement policies is another hurdle, potentially creating financial burdens for patients and practices. 

Ensuring patient adherence to prescribed treatments, particularly with complex dosing regimens or potential side effects, is also a common challenge, impacting the intended effectiveness of therapies. Moreover, identifying suitable patients for these advanced treatments requires careful consideration, as inaccuracies in patient selection may lead to suboptimal outcomes and unnecessary costs.

Addressing these challenges effectively involves providing comprehensive training for healthcare providers on patient selection, successful drug administration, and continuous monitoring of laboratory values and adverse events.  Collaborative efforts, involving physicians, pharmacists, specialty pharmacies, and insurers, are essential.

Strategies that focus on enhanced affordability, comprehensive education, and integration into clinical workflows are pivotal for the successful incorporation of advanced lipid-lowering therapies into routine practice.

Monitoring and Managing Side Effects

PCSK9 inhibitors are generally well-tolerated, however, associated adverse events may include mild injection-site swelling, muscle pain, fatigue, and flu-like symptoms. Less common side effects may include elevated liver enzymes or kidney problems. This is not an exhaustive list and side effects may vary. No significant drug-drug interactions have been identified.

For optimal patient safety, the prescribing physician should monitor LDL cholesterol for 4-8 weeks after initiating treatment with alirocumab, evolocumab, or inclisiran. If dose adjustments are made, remeasuring LDL after another 4-8 weeks is warranted.

Future Directions in Lipid Disorder Treatment

As research advances, the shift towards personalized medicine is becoming increasingly important. Tailoring lipid disorder treatments to unique patient profiles, encompassing genetic predispositions, lifestyle factors, and medication tolerability holds promise for more effective and targeted interventions.

Further exploration of combination therapies, synergizing existing treatments with novel therapies, may yield enhanced efficacy in reducing lipid levels, particularly in patients resistant to statins.

Furthermore, the identification and incorporation of novel biomarkers, and advanced measurements beyond traditional lipid profiles, have the potential to revolutionize treatment. Integrating comprehensive biomarker assessments may enable more accurate risk evaluation to guide clinicians in selecting the most appropriate and effective interventions for each patient.

[signup]

Key Takeaways

In addressing the global burden of cardiovascular disease, effective management of lipid disorders is critical. Advancements such as PCSK9 inhibitors and other emerging therapies offer targeted approaches beyond statins. PCSK9, a key enzyme in cholesterol metabolism, stands as a revolutionary target, with approved drugs like alirocumab, evolocumab, and inclisiran providing safe and effective options. Ongoing research explores a spectrum of innovative treatments. Despite their promise, implementing these novel therapies poses challenges that deserve attention. Looking ahead, personalized medicine, evolving therapies, and the integration of novel biomarkers are anticipated trends, reinforcing the need for continued research to optimize outcomes in lipid management.

The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.

Achuff, J. (Ed.). (2024, February 6). How to Lower Your Patient’s Triglycerides Using Root Cause Medicine. Rupa Health. https://www.rupahealth.com/post/how-to-lower-your-patients-triglycerides-using-root-cause-medicine

Adi prasad Bodapati, Hanif, A., Okafor, D. K., Katyal, G., Kaur, G., Ashraf, H., & Khan, S. (2023). PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis. Cureus, 15(10). https://doi.org/10.7759/cureus.46605

Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024). Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. Journal of Clinical Medicine, 13(5), 1251. https://doi.org/10.3390/jcm13051251

American Heart Association. (2018). Cholesterol Medications. Www.heart.org. https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia/cholesterol-medications

Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack

Austin, C. (2022, May 10). Enzyme. National Human Genome Research Institute. https://www.genome.gov/genetics-glossary/Enzyme

Bansal, A. B., & Cassagnol, M. (2019, November 27). Antilipemic Agents, HMG-CoA Reductase Inhibitors. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK542212/

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024). Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduction and Targeted Therapy, 9(1), 1–49. https://doi.org/10.1038/s41392-023-01690-3

Binod Pokhrel, & Levine, S. N. (2022, May 13). PCSK9 Inhibitors. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK448100/

Cavalier, J. S., Shah, N. P., & Blazing, M. A. (2023). Why Novel Therapies in Preventive Cardiology May Face a Marathon, Not a Sprint. Circulation, 148(11), 859–861. https://doi.org/10.1161/circulationaha.122.063099

CDC. (2023, November 29). National diabetes statistics report. CDC. https://www.cdc.gov/diabetes/data/statistics-report/index.html

Chandramahanti, S., & Farzam, K. (2024). Bempedoic Acid. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK594232/#:~:text=Bempedoic%20acid%20is%20a%20lipid

Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2017). RNA interference-based therapy and its delivery systems. Cancer and Metastasis Reviews, 37(1), 107–124. https://doi.org/10.1007/s10555-017-9717-6

Christie, J. (2023, January 6). A functional medicine approach to obesity and weight management. Rupa Health. https://www.rupahealth.com/post/an-integrative-approach-to-obesity

Cleveland Clinic. (2022, October 27). LDL cholesterol: What it is & how to lower it. Cleveland Clinic. https://my.clevelandclinic.org/health/articles/24391-ldl-cholesterol

Cleveland Clinic. (2024). Ezetimibe (Zetia): Uses & Side Effects. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/20153-ezetimibe-tablets

Cloyd, J. (2023a, April 7). Functional medicine high cholesterol protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-high-cholesterol-protocol

Cloyd, J. (2023b, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options

Cloyd, J. (2024a, March 1). What is Hyperlipidemia? Symptoms, Testing, and Treatments. Rupa Health. https://www.rupahealth.com/post/what-is-hyperlipidemia-symptoms-testing-and-treatments

Cloyd, J. (2024b, March 4). The Role of Statins in Managing High Cholesterol: Benefits and Side Effects. Rupa Health. https://www.rupahealth.com/post/the-role-of-statins-in-managing-high-cholesterol-benefits-and-side-effects

Cloyd, J. (2024c, March 5). How to Lower LDL Cholesterol Naturally: Evidence-Based Recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations

Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022). A Comprehensive Review of PCSK9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 27, 10742484221100107. https://doi.org/10.1177/10742484221100107

Dabravolski, S., Orekhov, N. A., Melnichenko, A., Sukhorukov, V. N., Popov, M. A., & Orekhov, A. (2024). Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128284695240219093612

Daglis, S. (2024, March 7). Emerging Biomarkers for Lipid Disorders: Beyond Traditional Lipid Profiles. Rupa Health. https://www.rupahealth.com/post/emerging-biomarkers-for-lipid-disorders-beyond-traditional-lipid-profiles

Duarte Lau, F., & Giugliano, R. P. (2023). Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. JAMA Cardiology, 8(9), 879–887. https://doi.org/10.1001/jamacardio.2023.2402

German, C. (2022, February 18). Homozygous Familial Hypercholesterolemia: Diagnosis and Emerging Therapies. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2022/02/18/18/04/homozygous-familial-hypercholesterolemia

German, C. A., & Shapiro, M. D. (2020). Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. European Cardiology Review, 15. https://doi.org/10.15420/ecr.2019.18

Gürgöze, M. T., Muller-Hansma, A. H. G., Schreuder, M. M., Galema-Boers, A. M. H., Boersma, E., & Roeters van Lennep, J. E. (2019). Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience. Clinical Pharmacology and Therapeutics, 105(2), 496–504. https://doi.org/10.1002/cpt.1193

Hassan, M. (2017). ANGPLT3: A novel modulator of lipid metabolism. Global Cardiology Science & Practice, 2017(1), e201706. https://doi.org/10.21542/gcsp.2017.6

Kastelein, J., Hsieh, A., Dicklin, M. R., Ditmarsch, M., & Davidson, M. H. (2023). Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports, 26(2), 35–44. https://doi.org/10.1007/s11883-023-01184-1

Katzmann, J., Gouni-Berthold, I., & Laufs, U. (2020, November 15). PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. Frontiers; Frontiers in Physiology. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.595819/full

Khakham, C. (2023, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs

Koren, M. J., Lundqvist, P., Bolognese, M., Neutel, J. M., Monsalvo, M. L., Yang, J., Kim, J. B., Scott, R., Wasserman, S. M., Bays, H., & MENDEL-2 Investigators. (2014). Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. Journal of the American College of Cardiology, 63(23), 2531–2540. https://doi.org/10.1016/j.jacc.2014.03.018

Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Peña Genao, E., Echavarria Uceta, R., & Guzman, E. (2020). Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology : Advances and Applications, 12, 191–202. https://doi.org/10.2147/CPAA.S288831

Laakso, M., & Lilian Fernandes Silva. (2023). Statins and risk of type 2 diabetes: mechanism and clinical implications. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1239335

Maholy, N. (2023, March 9). Integrative Medicine Protocol For Reversing Type 2 Diabetes. Rupa Health. https://www.rupahealth.com/post/integrative-medicine-protocol-for-reversing-type-2-diabetes

Mayo Clinic. (2024a, February 1). Alirocumab (Subcutaneous Route) Description and Brand Names - Mayo Clinic. Www.mayoclinic.org. https://www.mayoclinic.org/drugs-supplements/alirocumab-subcutaneous-route/description/drg-20151256

Mayo Clinic. (2024b, February 1). Evolocumab (Subcutaneous Route) Description and Brand Names - Mayo Clinic. Www.mayoclinic.org. https://www.mayoclinic.org/drugs-supplements/evolocumab-subcutaneous-route/description/drg-20152627

Mayo Clinic. (2024c, February 1). Inclisiran (Subcutaneous Route) Description and Brand Names - Mayo Clinic. Www.mayoclinic.org. https://www.mayoclinic.org/drugs-supplements/inclisiran-subcutaneous-route/description/drg-20528309

Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Di Luozzo, M., Marchei, M., & Sangiorgi, G. M. (2022). Current Options and Future Perspectives in the Treatment of Dyslipidemia. Journal of Clinical Medicine, 11(16), 4716. https://doi.org/10.3390/jcm11164716

National Human Genome Research Institute. (2019). Ribonucleic Acid (RNA). Genome.gov. https://www.genome.gov/genetics-glossary/RNA-Ribonucleic-Acid

National Institutes of Health. (2011, February 2). https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monoclonal-antibody#. Www.cancer.gov. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monoclonal-antibody#

National Institutes of Health. (2023, July). Statins. PubMed; Organization of Teratology Information Specialists (OTIS). https://www.ncbi.nlm.nih.gov/books/NBK582962/#:~:text=Does%20taking%20a%20statin%20increase%20the%20chance%20of%20birth%20defects

National Library of Medicine. (n.d.-a). LDLR gene: MedlinePlus Genetics. Medlineplus.gov. https://medlineplus.gov/genetics/gene/ldlr/#:~:text=The%20LDLR%20gene%20provides%20instructions

National Library of Medicine. (n.d.-b). Subcutaneous (SQ) injections: MedlinePlus Medical Encyclopedia. Medlineplus.gov. https://medlineplus.gov/ency/patientinstructions/000430.htm#:~:text=Subcutaneous%20(SQ%20or%20Sub%2DQ

Pinal-Fernandez, I., Casal-Dominguez, M., & Mammen, A. L. (2018). Statins: pros and cons. Medicina Clínica, 150(10), 398–402. https://doi.org/10.1016/j.medcli.2017.11.030

Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Wright, R. S., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., & Landmesser, U. (2023). Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology, 0(0). https://doi.org/10.1016/S2213-8587(22)00353-9

Reiner, Ž. (2014). Resistance and intolerance to statins. Nutrition, Metabolism, and Cardiovascular Diseases , 24(10), 1057–1066. https://doi.org/10.1016/j.numecd.2014.05.009

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., Sever, P. S., & Pedersen, T. R. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376(18), 1713–1722. https://doi.org/10.1056/nejmoa1615664

Sen, S. (2020). Messenger RNA (mRNA). Genome.gov. https://www.genome.gov/genetics-glossary/messenger-rna

Sosnowska, B., Adach, W., Surma, S., Rosenson, R. S., & Banach, M. (2022). Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. Journal of Clinical Medicine, 12(1), 168. https://doi.org/10.3390/jcm12010168

Stankov, S., & Cuchel, M. (2023, January 14). Gene editing for dyslipidemias: New tools to “cut” lipids. ScienceDirect; Atherosclerosis. https://www.sciencedirect.com/science/article/abs/pii/S0021915023000114

Stroes, E., Stiekema, L., & Rosenson, R. (2024, January 10). UpToDate. Www.uptodate.com. https://www.uptodate.com/contents/pcsk9-inhibitors-pharmacology-adverse-effects-and-use

Tsimikas, S. (2017). A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69(6), 692–711. https://doi.org/10.1016/j.jacc.2016.11.042

UpToDate. (n.d.-a). UpToDate. Www.uptodate.com. Retrieved March 9, 2024, from https://www.uptodate.com/contents/alirocumab-drug-information?topicRef=106888&source=see_link

UpToDate. (n.d.-b). UpToDate. Www.uptodate.com. Retrieved March 9, 2024, from https://www.uptodate.com/contents/evolocumab-drug-information?topicRef=106888&source=see_link

UpToDate. (n.d.-c). UpToDate. Www.uptodate.com. Retrieved March 9, 2024, from https://www.uptodate.com/contents/inclisiran-drug-information?topicRef=106888&source=see_link

Weinberg, J. (2022, May 3). Tiredness, Weight Loss, And Itching Are Signs Of This Dangerous Liver Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-non-alcoholic-fatty-liver-disease

Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally

World Health Organization. (2020, December 9). The Top 10 Causes of Death. World Health Organization; WHO. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Yale Medicine. (n.d.). Atherosclerosis. Yale Medicine. Retrieved March 8, 2024, from https://www.yalemedicine.org/conditions/atherosclerosis#:~:text=Atherosclerosis%20is%20a%20disease%20of

Yoshimura, H. (2023, July 17). Using Functional Medicine As Personalized Medicine. Rupa Health. https://www.rupahealth.com/post/using-functional-medicine-as-personalized-medicine

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.